2009 PHARMACOVIGILANCE POLICY This document and its contents are the confidential property of Biocon Ltd. It should not be copied, reproduced, modified, altered, or circulated to any third party, in any form or media, w - Postmarketing surveillance - Document - PDFSEARCH.IO

First Page	Meta Content
	2009 PHARMACOVIGILANCE POLICY This document and its contents are the confidential property of Biocon Ltd. It should not be copied, reproduced, modified, altered, or circulated to any third party, in any form or media, w Add to Reading List Document Date: 2009-11-12 18:24:13 Open Document File Size: 279,65 KB Share Result on Facebook Company Biocon Ltd. / PHARMACOVIGILANCE POLICY / / Event Product Recall / M&A / Product Issues / / IndustryTerm to all marketed products / particular product / risk management / web-online / investigational and marketed products / investigational products / / Organization Safety Committee / World Health Organization / Regulatory Authority / / Position physician / EXECUTIVE / / Product medicine / / Technology drug development / / SocialTag Health Research Pharmaceutical industry Pharmaceuticals policy Drug safety Pharmacovigilance Postmarketing surveillance Adverse effect Adverse event Clinical research

2009 PHARMACOVIGILANCE POLICY This document and its contents are the confidential property of Biocon Ltd. It should not be copied, reproduced, modified, altered, or circulated to any third party, in any form or media, wAdd to Reading List